Tiziana Life Sciences Ltd
NASDAQ: TLSA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ivor R. Elrifi
- Employees
- 9
- Headquarters
- London, United Kingdom
- IPO year
- 2018
- Market cap
- $66.6M
- Website
- https://www.tizianalifesciences.com
Loading TLSA…
Loading profile data…Frequently asked questions about TLSA
What does Tiziana Life Sciences Ltd (TLSA) do?
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's...
Where does TLSA trade?
Tiziana Life Sciences Ltd (TLSA) trades on the NASDAQ Global Market.
What sector is TLSA in?
Tiziana Life Sciences Ltd (TLSA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Tiziana Life Sciences Ltd?
Ivor R. Elrifi is the chief executive officer of Tiziana Life Sciences Ltd (TLSA).
Where is Tiziana Life Sciences Ltd headquartered?
Tiziana Life Sciences Ltd is headquartered in United Kingdom.
Does TLSA pay a dividend?
Tiziana Life Sciences Ltd (TLSA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TLSA go public?
Tiziana Life Sciences Ltd (TLSA) completed its initial public offering in 2018.
Is TLSA an ADR?
Yes — TLSA is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Tiziana Life Sciences Ltd reporting and dividends follow the underlying issuer.